ALSO NOTED: The WSJ profiles the FDA's lead regulator for cancer; Living Cell raises funds; new approach to gene therapy; and m

> The argument over the FDA's role in regulating cancer therapies often comes down to one man: Dr. Richard Pazdur, a veteran oncologist and chief of the agency's oncology office. Report

> A group of scientists have come together to highlight the revolution in personalized medicine that is being ushered in by dramatic new gains in genetic research. The Journal of the American Medical Association's March 19 issue is devoted to studies regarding genomics. Report

> Living Cell Technologies announced that it has received $6 million in relation to the placement of 24,150,408 ordinary shares, at a price of A$0.29 per share. Release

> A team of scientists led by British Nobel laureate Sir Aaron Klug has advanced a new approach to gene therapy. Report

> Nicox has struck a deal with Archimica on the commercial manufacturing of  naproxcinod, an osteoarthritis drug it plans to seek approval for in mid-2009. Release

> What do you get when you mix 20 drug developers active in the diabetes field with a room full of geneticists? Hopefully, a new generation of therapies that pinpoint subsets of the disease. Report

> Scientists are heralding a "breakthrough" on blindness therapies. Report

> Raptor Pharmaceuticals says that its clinical development subsidiary, Bennu Pharmaceuticals, has acquired an exclusive worldwide license to intellectual property from the University of California, San Diego around the use of Cysteamine, and delayed release Cysteamine for the treatment of Non-alcoholic Steatohepatitis. Release 

And Finally... The stem cell market has grown from zero to $87 million in less than three years, and analysts at the year's Stem Cell Summit were bullishly forecasting its growth to $8.5 billion over the next decade. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.